drugset / Trial / NCT02077452

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HMS5552 in Patients With Type 2 Diabetes

NCT02077452

Phase 1 Completed 53 enrolled Hua Medicine Limited
RandomizedSingle-groupQuadruple-blindTreatment

Summary

The objectives of this study is to determine the safety, tolerability, pharmacokinetics and pharmacodynamics of HMS5552 following multiple ascending doses in patients with type 2 diabetes mellitus.

Timeline

Start
2014-03
Primary completion
2014-09
Completion
2014-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Dorzagliatin Small molecule Oral